SG Americas Securities
YMAB

SG Americas Securities’s Y-mAbs Therapeutics YMAB Stock Holding History

SG Americas Securities’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,284
Closed -$59K – 3682
2025
Q1 		$59K Sell
13,284
-4,445
-25% -$25.8K ﹤0.01% 3201
2024
Q4 		$139K Buy
17,729
+4,163
+31% +$50.7K ﹤0.01% 2474
2024
Q3 		$178K Buy
+13,566
New +$172K ﹤0.01% 2599
2024
Q2 		– Sell
-11,963
Closed -$195K – 3370
2024
Q1 		$195K Sell
11,963
-9,596
-45% -$129K ﹤0.01% 1990
2023
Q4 		$147K Buy
21,559
+3,210
+17% +$18.6K ﹤0.01% 2437
2023
Q3 		$100K Buy
+18,349
New +$107K ﹤0.01% 2796
2023
Q2 		– Sell
-21,735
Closed -$109K – 3275
2023
Q1 		$109K Buy
21,735
+11,676
+116% +$47.7K ﹤0.01% 2849
2022
Q4 		$49K Sell
10,059
-6,483
-39% -$47.1K ﹤0.01% 2842
2022
Q3 		$239K Sell
16,542
-1,675
-9% -$27.7K ﹤0.01% 2169
2022
Q2 		$276K Buy
+18,217
New +$213K ﹤0.01% 2439
2022
Q1 		– Sell
-15,020
Closed -$243K – 3516
2021
Q4 		$243K Sell
15,020
-10,790
-42% -$231K ﹤0.01% 2565
2021
Q3 		$737K Buy
25,810
+374
+1% +$11.8K ﹤0.01% 2174
2021
Q2 		$860K Sell
25,436
-3,730
-13% -$120K ﹤0.01% 1661
2021
Q1 		$882K Sell
29,166
-27,546
-49% -$1.13M ﹤0.01% 1638
2020
Q4 		$2.81M Sell
56,712
-20,774
-27% -$961K 0.02% 858
2020
Q3 		$2.98M Buy
77,486
+72,163
+1,356% +$2.87M 0.02% 538
2020
Q2 		$230K Sell
5,323
-210
-4% -$7.94K ﹤0.01% 2739
2020
Q1 		$144K Buy
5,533
+2,151
+64% +$62.5K ﹤0.01% 2739
2019
Q4 		$106K Buy
+3,382
New +$100K ﹤0.01% 2927

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

SG Americas Securities's YMAB Position: Q2 2025 in Review

SG Americas Securities sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 13,284 shares — an estimated $59K sold.

SG Americas Securities first reported a position in YMAB in Q4 2019 and held it in 19 quarters. The position peaked at $2.98M in Q3 2020. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • SG Americas Securities reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 13,284 Y-mAbs Therapeutics shares in Q2 2025, an estimated $59K.
  • SG Americas Securities first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 19 quarters.
  • SG Americas Securities's Y-mAbs Therapeutics position peaked at $2.98M in Q3 2020.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.